Spotlight
Obituaries
Classifieds
Families First
VCAs Best of Guide
News
Weather
Specialists
Sports
Business
Consumer
Health
Life
Out & About
Login
Recommended
After Charlotte stabbing, a political push for death penalty in NC
Recommended
Couple battling illness says contractor took money, didn't finish job
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Merck Sharp & Dohme
U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection
July 10, 2025
From
Merck Sharp & Dohme
Via
Business Wire
Tickers
MRK
WINREVAIR™ (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the Phase 3 ZENITH Trial
March 31, 2025
From
Merck Sharp & Dohme
Via
Business Wire
Tickers
MRK
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.